Results 11 to 20 of about 35,539 (289)

Antibody Levels at 3-Years Follow-Up of a Third Dose of Measles-Mumps-Rubella Vaccine in Young Adults [PDF]

Vaccines, 2022
Mumps outbreaks and breakthrough infections of measles and rubella have raised concerns about waning of vaccine-induced immunity after two doses of measles-mumps-rubella (MMR) vaccination.
Patricia Kaaijk, Alienke J. Wijmenga-Monsuur, Hinke I. ten Hulscher, Jeroen Kerkhof, Gaby Smits, Mioara Alina Nicolaie, Marianne A. van Houten, Rob S. van Binnendijk   +7 more
doaj   +5 more sources

Measles-Mumps-Rubella Vaccine and COVID-19 Relationship [PDF]

mBio, 2020
I have read the article by Fidel and Noverr with great interest (1). As told in the article, could measles-mumps-rubella (MMR) vaccine really be a “low-risk–high-reward” measure in COVID-19? However, I have several concerns about their opinion/hypothesis posed in their article (1).
Özdemir Ö.
europepmc   +4 more sources

Measles, Mumps, Rubella Vaccine (PRIORIX): Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. [PDF]

MMWR Morb Mortal Wkly Rep, 2022
Vaccination is the main means for preventing measles, mumps, and rubella virus infections and their related complications (1,2). Achieving and maintaining high 2-dose measles, mumps, and rubella vaccination coverage in the United States has led to ...
Krow-Lucal E, Marin M, Shepersky L, Bahta L, Loehr J, Dooling K.   +5 more
europepmc   +2 more sources

Dynamics of the Antibody Response After a Third Dose of Measles-Mumps-Rubella Vaccine Indicate a Slower Decline Compared With a Second Dose. [PDF]

Open Forum Infect Dis, 2020
Background Breakthrough infections of measles and mumps have raised concerns about the duration of vaccine-induced immunity, which might be improved by a third dose of measles-mumps-rubella vaccine (MMR3).
Kaaijk P, Nicolaie MA, van Rooijen D, van Houten MA, van der Klis FR, Buisman AM, van Binnendijk RS.   +6 more
europepmc   +2 more sources

A review of safety and immunogenicity of a novel measles, mumps, rubella (MMR) vaccine

Human Vaccines & Immunotherapeutics
Measles, mumps, and rubella (MMR) are highly infectious viral diseases affecting young children and have high secondary attack rates. Present MMR vaccines show consistent seroconversion rates for anti-measles and anti-rubella antibodies with variable ...
Nitin Shah, Apurba Ghosh, Kishore Kumar, Trayambak Dutta, Manish Mahajan   +4 more
doaj   +2 more sources

A Third Dose of Measles-Mumps-Rubella Vaccine to Improve Immunity Against Mumps in Young Adults [PDF]

Journal of Infectious Diseases, 2019
BACKGROUND Waning of vaccine-induced immunity is considered to play a central role in the reemergence of mumps among vaccinated young adults. The aim of the present study was to investigate antibody responses and safety of a third dose of measles-mumps ...
Patricia Kaaijk, Alienke J. Wijmenga‐Monsuur, Marlies A. van Houten, Irene Veldhuijzen, Hinke I ten Hulscher, Jeroen Kerkhof, Fiona van der Klis, Rob van Binnendijk   +7 more
openalex   +2 more sources

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study [PDF]

Human Vaccines & Immunotherapeutics, 2018
The introduction of vaccination programs against measles, mumps, and rubella (MMR) led to significant global reduction in morbidity and mortality from these diseases.
Remon Abu‐Elyazeed, William Jennings, Randall Severance, Michael J. Noss, Adrian Caplanusi, Michael Povey, Ouzama Henry   +6 more
openalex   +2 more sources

A Comparative Prospective Study to Assess Efficacy of Intralesional MMR (Measles, Mumps, Rubella) Vaccine and Intralesional Vitamin D3 in Treatment of Nongenital Warts [PDF]

Health Science Reports, Volume 8, Issue 5, May 2025.
ABSTRACT Background and Aims Intralesional immunotherapy is an upcoming method of wart treatment with fewer side effects and this study aims to assess and compare the efficacy of intralesional MMR vaccine and vitamin D3 in the treatment of nongenital warts.
Bibisha Baaniya, Suchana Marahatta, Raunak Dahal, Nidhi Shah   +3 more
wiley   +2 more sources

Persistence of Rubella Antibodies after 2 Doses of Measles‐Mumps‐Rubella Vaccine [PDF]

Journal of Infectious Diseases, 2009
BACKGROUND Since 1990, most schoolchildren in the United States have received a second dose of measles-mumps-rubella vaccine (MMR2) at kindergarten entry. Elimination of endemic rubella virus circulation in the United States was declared in 2004.
Charles W. LeBaron, Bagher Forghani, L Matter, Susan E. Reef, Carol L. Beck, Daoling Bi, Cynthia Cossen, Bradley J. Sullivan   +7 more
openalex   +2 more sources

Controversies in Vaccination with Measles, Mumps, Rubella (MMR) Vaccine [PDF]

The Australian Journal of Hospital Pharmacy, 1998
Many people remember the extensive adverse publicity surrounding pertussis vaccine in the 1970s which led to public concern about the safety of vaccines. Subsequently, follow‐up indicated no causal link between pertussis vaccination and brain damage although the risk of recurrent collapse (shock‐like syndrome or so‐called hypotonic‐hyporesponsive ...
Murray D. Bailey
openaire   +3 more sources